Double Bond Pharmaceutical

Executive Summary

Double Bond Pharmaceutical International AB is a Swedish biotech company focused on improving established drugs through novel drug delivery systems. By redeveloping known active pharmaceutical ingredients with alternative routes of administration, the company aims to create safer and more effective treatments for brain cancer, liver cancer, and pneumonia. Founded in 2008 and headquartered in Uppsala, Sweden, the company operates in the small molecules category and remains privately held. Despite limited public information on its pipeline or financials, Double Bond's strategy of repurposing approved drugs reduces development risk and could offer faster regulatory pathways. The company's key therapeutic areas address significant unmet medical needs, particularly in oncology and infectious disease. While no recent clinical updates are available, the company's approach positions it for potential partnerships or licensing deals. However, the absence of disclosed revenue or funding raises questions about near-term viability and progress.

Upcoming Catalysts (preview)

• Q1 2027Initiation or update of Phase I/II trial for lead drug candidate in brain cancer30% success
• Q4 2026Announcement of strategic partnership or licensing agreement for liver cancer program40% success
• Q3 2026Publication of preclinical data for pneumonia drug delivery platform50% success